Considering Evusheld™?

Evusheld™ (tixagevimab/cilgavimab) is a monoclonal antibody approved for **pre-exposure prophylaxis** of COVID-19. Evusheld™ is **not** a substitute for vaccination.



In Saskatchewan, Evusheld™ may only be considered in individuals who:

are severely immunocompromised + **have additional risk factors for poor outcomes from COVID-19** + **do not have known cardiovascular disease**

The evidence for pre-exposure prophylaxis comes from **PROVENT**—a clinical trial done Nov. 2020–Mar. 2021. Real world evidence is limited.

THEN: Alpha, Beta, Gamma and Delta; vaccines and treatments limited.
NOW: Omicron; vaccines and treatments available.

BENEFIT

Fewer than 4% of people included in the trial were immunocompromised.

Placebo	17 cases/1731 people	0.98% rate of symptomatic COVID-19
Evusheld™300mg	8 cases/3441 people	0.23% rate of symptomatic COVID-19
	77% relative risk reduction	0.75% absolute risk reduction

Resistance has been demonstrated and higher dosing may be necessary.

Uncertain impact on important outcomes like hospitalizations, severe illness, and death.

133 people need to be given Evusheld™ to prevent one person from being infected with and having symptoms of COVID-19 at 3 months versus placebo.

RISK

Each dose requires 2 gluteal IM injections.

- Evusheld™ appears to be well tolerated. Side effects are mild to moderate and may include injection site reactions, hypersensitivity, headache, fatigue. Anaphylaxis is rare.
- No known drug interactions but unknown impact on COVID-19 vaccines and treatments.
- In PROVENT, serious cardiac adverse events occurred more frequently in Evusheld™ group than placebo. No causal relationship established.

For every 263 people who received Evusheld™, one person had a serious cardiac adverse event at 6 months versus placebo.

Use for pre-exposure prophylaxis may affect future eligibility for COVID-19 therapies until additional evidence available.

UNKNOWN

- protection against emerging variants?
- duration of protection?
- repeat dosing required?

Preventing outcomes like serious illness, hospitalization, and death are important goals for COVID-19 therapies, and pre-exposure use of Evusheld™ only has evidence for preventing symptomatic COVID-19 at this time. Further, there are potential risks and important gaps in evidence. The Saskatchewan Health Authority's Therapeutics Expert Group is currently not recommending the use of Evusheld™ for pre-exposure prophylaxis and suggests that further evidence and experience are needed.

medSask
YOUR MEDICATION INFORMATION SERVICE

Saskatchewan

Please consult the Evusheld™ Clinical Practice Guide for additional information and references. COVID-19 information is rapidly evolving and subject to change.

Revised: 10 June 2022